Economic model of albumin infusion in septic shock: The EMAISS study
作者： Bertrand Guidet , Idir Ghout , Jacques Ropers , Philippe Aegerter
DOI: 10.1111/AAS.13559
关键词:
摘要: Background: The cost-effectiveness of albumin-based fluid support in patients with septic shock is currently unknown. Methods: In a simulation study, we compared standard medical practice and systematic 20% albumin infusion. study population consisted admitted to one the 28 ICUs belonging Cub-Rea regional database between 1 January 2014 31 December 2016. Cost estimates were based on French diagnosis-related groups fixed daily prices. Estimation mortality reduction relied ALBIOS trial data documenting Risk Ratio 0.87 non-preplanned subgroup shock. Life expectancy was estimated follow up 184 year 2000 same ICUs. Several sensitivity analyses performed including one-way Deterministic Sensitivity Analysis (DSA) Probabilistic multivariate (PSA). Results: About 6406 included. base-case scenario, mean live years gained 0.49. extra cost using €480 per year. €974. confirmed robustness results. probability being cost-effective 95% 97% for threshold at €20 000 €30 000 life-year saved, respectively. Conclusion: Based risk observed analysis dataset, application results may suggest that infusion likely
archives-ouvertes.fr
sci-hub.se 参考文章(36)
Albumin replacement in severe sepsis or septic shock. The New England Journal of Medicine. ,vol. 371, pp. 83- ,(2014) , 10.1056/NEJMC1405675
Leonardo Gottin, Jean Louis Vincent, Type of fluid in severe sepsis and septic shock. Minerva Anestesiologica. ,vol. 77, pp. 1190- 1196 ,(2011)
B. Guidet, R. Beale, Should cost considerations be included in medical decisions? Yes Intensive Care Medicine. ,vol. 41, pp. 1838- 1840 ,(2015) , 10.1007/S00134-015-3988-6
J.Robert Beck, Jerome P. Kassirer, Stephen G. Pauker, A convenient approximation of life expectancy (the “DEALE”): I. validation of the method The American Journal of Medicine. ,vol. 73, pp. 883- 888 ,(1982) , 10.1016/0002-9343(82)90786-0
Jean-Louis Vincent, Fluid management: the pharmacoeconomic dimension. Critical Care. ,vol. 4, pp. 1- 1 ,(2000) , 10.1186/CC969
Libing Jiang, Shouyin Jiang, Mao Zhang, Zhongjun Zheng, Yuefeng Ma, Albumin versus Other Fluids for Fluid Resuscitation in Patients with Sepsis: A Meta-Analysis PLoS ONE. ,vol. 9, pp. e114666- ,(2014) , 10.1371/JOURNAL.PONE.0114666
A. Patel, M. A. Laffan, U. Waheed, S. J. Brett, Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality BMJ. ,vol. 349, ,(2014) , 10.1136/BMJ.G4561
Enrique Moret, Matthias W. Jacob, Marco Ranucci, Alexey A. Schramko, Albumin-Beyond Fluid Replacement in Cardiopulmonary Bypass Surgery: Why, How, and When? Seminars in Cardiothoracic and Vascular Anesthesia. ,vol. 18, pp. 252- 259 ,(2014) , 10.1177/1089253214535667
Derek C. Angus, Walter T. Linde-Zwirble, Jeffrey Lidicker, Gilles Clermont, Joseph Carcillo, Michael R. Pinsky, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine. ,vol. 29, pp. 1303- 1310 ,(2001) , 10.1097/00003246-200107000-00002
Andrew A. Quartin, Magnitude and Duration of the Effect of Sepsis on Survival JAMA: The Journal of the American Medical Association. ,vol. 277, pp. 1058- 1063 ,(1997) , 10.1001/JAMA.1997.03540370048035